Article List

WPRIM Management System> DCMS> Hanyang Medical Reviews> 2007> 27

Volume: 27

1. Characteristic Features of H. Pylori infection in Children.	Page:65—75
2. Prevalence Rate and Transmission Route of H. pylori.	Page:58—64
3. Diagnosis of Helicobacter pylori Infection.	Page:51—57
4. Extragastric diseases associated with Helicobacter pylori infection.	Page:41—50
5. Pathogenesis of Helicobacter pylori-induced Gastric Cell Injury.	Page:34—40
6. Virulence factors of Helicobacter pylori and their clinical significances.	Page:28—33
7. Structural and Physio-chemical Properties of Helicobacter pylori.	Page:4—27
8. The Role of Positron Emission Tomography(PET) in Radiation Treatment Planning.	Page:76—85
9. The Clinical Role of FDG PET in Malignant Lymphoma.	Page:66—75
10. PET Imaging for Gynecologic Malignancy.	Page:59—65
11. The role of Positron Emission Tomography in hepatobiliary cancers.	Page:52—58
12. The Role of fluorodeoxyglucose PET in the management of breast cancer.	Page:43—51
13. PET oncology; Lung cancer.	Page:37—42
14. Clinical Application of F-18 FDG PET/PET-CT in gastrointestinal tumors.	Page:28—36
15. The Use of PET in Esophageal Cancer.	Page:23—27
16. Clinical Application of PET in Head and Neck Cancer.	Page:16—22
17. New Trend of tumor PET imaging radiopharmaceuticals.	Page:4—15
18. Molecular Pathogenesis of Pancreatic Cancer.	Page:76—84
19. Diagnostic Criteria for Autoimmune Chronic Pancreatitis.	Page:66—75
20. Chronic Pancreatitis with Fibrogenesis.	Page:60—65
21. Pancreatic Exocrine and Endocrine Cell Differentiation during Pancreatic Regeneration.	Page:49—59
22. Pathogenesis of Acute Pancreatitis.	Page:42—48
23. What's New? Oral Dissolution Therapy for Gallstone.	Page:35—41
24. Molecular Genetics of Cholesterol Gallstone Disease; LITH Genes.	Page:29—34
25. Transporters and Nuclear Hormone Receptors associated with Cholesterol Metabolism in Gallbladder Epithelial Cells.	Page:20—28
26. Animal Models for Biliary Diseases.	Page:13—19
27. The Biology of the Cholangiocytes.	Page:4—12
28. Reoperation of Valvular Heart Disease.	Page:65—70
29. Reoperation of Valvular Heart Disease.	Page:65—70
30. Surgical Treatment of Infective Endocarditis.	Page:57—64
31. Surgical Treatment of Infective Endocarditis.	Page:57—64
32. Minimally Invasive Mitral Valve Surgery.	Page:49—56
33. Minimally Invasive Mitral Valve Surgery.	Page:49—56
34. Homograft or Autograft Valve Replacement.	Page:44—48
35. Homograft or Autograft Valve Replacement.	Page:44—48
36. Mitral Valve Repair.	Page:36—43
37. Mitral Valve Repair.	Page:36—43
38. Aortic Valve Repair.	Page:28—35
39. Aortic Valve Repair.	Page:28—35
40. Artificial Heart Valve Replacement.	Page:18—27
41. Artificial Heart Valve Replacement.	Page:18—27
42. Selection and Complications of Prosthetic Heart Valves.	Page:9—17
43. Selection and Complications of Prosthetic Heart Valves.	Page:9—17
44. Optimal Timing of Surgery of Mitral Regurgitation.	Page:4—8
45. Optimal Timing of Surgery of Mitral Regurgitation.	Page:4—8
46. Current Status of Health Insurance in the Treatment of Helicobacter Pylori Infection.	Page:103—106
47. Current concepts in the treatment of H. pylori infection and H. pylori vaccines.	Page:92—102
48. Antibiotic Resistance in Helicobacter pylori.	Page:76—91